C1-GBM is characterized by an immune-infiltrated microenvironment with significant IL6 pathway activity, whereas C2-GBM is marked by tumor driver and activation of G2/M checkpoint for the cell cycle. The gene discussed is IL6; the disease is glioblastoma.